glp-1/gcgr dual agonist Design of novel Xenopus GLP-1-based glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists The dual GLP-1/glucagon receptor agonist

Another way in which DPP-4 inhibitors may affect bone metabolism is through a pathway linked to 25(OH)-D levels (Vitamin D, [136])

3.2 GM and hormone metabolism disorders Hyperandrogenemia (HA) is also a pivotal clinical manifestation in patients with PCOS, potentially stemming from complex interplays involving the Hypothalamic-pituitary-gonadal (HPG) axis, adrenal function abnormalities, dysregulation of glucose and lipid metabolism, intestinal microbiota imbalances, chronic inflammation, and genetic predispositions (39)

Anstey KJ, Ee N, Eramudugolla R, Jagger C, Peters R

Pharmaceutical companies created various GLP-1 analogs with different structural modifications to optimize pharmacokinetic properties, dosing convenience, and clinical efficacy